Charles River Laboratories Intl. Inc vs Google Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while Google Inc trades at $356.4 (market cap $4.37T). The key difference: Google Inc is far larger — about 392.3× Charles River Laboratories Intl. Inc's market cap, and Google Inc pays a 0.25% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | GOOG | |
|---|---|---|
Market Cap | $11.14B | $4.37T |
Sector | Health | Technology |
52-Week High | $233.60 | $399.06 |
52-Week Low | $145.57 | $183.10 |
Enterprise Value | $14.00B | $4.34T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.25% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Alphabet (GOOG) trades at $350.67, down 1.23% amid bearish technical signals, though fundamentals remain robust with strong earnings beats and 32.8% net margin. Revenue grew to $402.84B in 2025, while analyst consensus is overwhelmingly bullish with an 86.84% buy rating and $457.50 price target. Recent news highlights AI advancements and regulatory scrutiny.
Outlook is positive given earnings momentum and AI leadership, but risks include regulatory probes and high valuation multiples. The stock offers growth potential with disciplined risk management advised amid technical weakness and competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →